Continuous Plasma Virus Inactivation Device with Methylene Blue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing plasma virus inactivation techniques are limited to single-bag treatments and are not suitable for large-scale or continuous plasma treatment, lacking the capability for real-time processing and back-transfusion.
Innovation Solution
A treatment device comprising a blood separation unit and a light treatment unit connected through conduits with transport pumps and shutoff valves, allowing for continuous and cyclic treatment of plasma using methylene blue photochemical inactivation, enabling real-time plasma exchange and back-transfusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing plasma virus inactivation technique is used, then virus inactivation effect is achieved, but treatment capacity is limited to single bag and cannot be used for large-scale continuous treatment
Solution Approach 1:
The system is divided into multiple functional modules: blood separation device, light treatment device, dosing device, and circulation system. Each module can independently process plasma, enabling continuous treatment of multiple plasma bags sequentially without interrupting the overall process.
Solution Approach 2:
The patent implements continuous plasma treatment through a closed-loop circulation system where plasma is continuously pumped through the light treatment device and back to the patient. The system can continuously process multiple plasma bags in sequence, maintaining uninterrupted virus inactivation activity.
2Productivity
If existing plasma virus inactivation technique is used, then virus inactivation is performed, but real-time treatment and back-transfusion capability is lacking
Solution Approach 1:
The system incorporates real-time monitoring and feedback mechanisms where the circulation pump continuously monitors plasma flow and can automatically adjust treatment parameters. The closed-loop system allows real-time observation of treatment effects and immediate adjustment of dosing and circulation rates.
Solution Approach 2:
The system enables automatic back-transfusion where treated plasma is automatically returned to the patient through the same circulation system. The dosing device automatically controls the addition of antiviral agents, and the circulation pump automatically manages plasma flow, reducing manual intervention and enabling real-time self-regulating treatment.
3Productivity
If single bag plasma treatment is performed, then treatment process is simple, but treatment efficiency and capacity are low
Solution Approach 1:
The patent combines multiple functions into integrated devices: the blood separation device and light treatment device are coupled in sequence, with the dosing device integrated into the circulation system. This merging of functions reduces the number of separate operations needed and improves treatment efficiency despite increased system complexity.
Solution Approach 2:
The circulation system serves multiple functions: it pumps plasma through the light treatment device, returns treated plasma to the patient, and facilitates back-transfusion. The dosing device can handle both liquid and solid antiviral agents. This multi-functionality reduces the need for separate dedicated components for each operation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device significantly enhances treatment capacity and efficiency, enabling continuous and efficient plasma virus inactivation with wide application prospects by allowing real-time treatment and back-transfusion in a closed system.
Implementation Method 1
methylene blue photochemical plasma virus inactivation
Implementation Method 2
The aqueous solution of methylene blue is blue in an oxidative environment and can be reduced to a colorless state when contacted with reducing agents
Data Source
AI summary
A device and method can be used for clinical virus inactivation treatment to automatically, continuously and cyclically treat plasma of a patient in a closed system. The disclosed plasma treatment device may be used for an anti-viral agent such as, for example, methylene blue photochemical plasma virus inactivation. The plasma treatment device can perform real-time treatment to the plasma in the closed system on the basis of the principle of plasma exchange and can realize real-time back-transfusion during treatment.